National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Condition(s) studied

Study summary

This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.

Eligibility

Primary outcome measure(s)

• Long-term overall remission rate — 5 years
  Proportion of the participants with an overall remission. To investigate the long-term efficacy of Chimeric antigen receptors (CAR) T cell therapy in Chinese patients with various hematological malignancies.

Trial sites (1)

More Institute of Hematology & Blood Diseases Hospital, China trials in China

Other trials for the same condition